더 옳고, 더 아름다운 선택의 삶

임종래 지역재단 2009 지역리더 Vol.8 No.-

생명은 알을 깨는 데서 시작한다 ─데미안

임종래 지역재단 2008 지역리더 Vol.2 No.-

다낭성 난소증후군 환자의 아디포넥틴, TNF-α, IL-6 농도와 인슐린저항성의 관계

김영아,고경수,임경호,노정현,김동준,박정현,이병두,엄태현,조종래,장나영,권수경,이순희 대한당뇨병학회 2006 Diabetes and Metabolism Journal Vol.30 No.2

-Background: To determine plasma adipokines such as adiponectin, IL-6 and TNF-α concentrations in women with and without polycystic ovary syndrome (PCOS) and to assess possible correlations of adipocytokines to the hormonal and metabolic parameters, including measures of insulin resistance (IR). Methods: Forty-four selected women were classified as follows: 13 obese (body mass index [BMI] ≥ 25 kg/m2) with PCOS; 15 non-obese (BMI < 25 kg/m2) with PCOS; 8 obese without PCOS, and 8 non-obese without PCOS. Blood samples were collected from all women with or without PCOS after an overnight fast. Serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone, 17-α-hydroxyprogesterone, dehydroepiandrosterone sulfate (DHEA-S), sex hormone-binding globulin (SHBG), insulin, glucose, adiponectin, TNF-α and IL-6 were measured. Measures of IR included HOMA-IR and QUICKI.Results: In non-obese group, fasting insulin levels and HOMA-IR in PCOS were significantly higher compared to control. However, Adiponectin, TNF-α and IL-6 concentrations were found not to be different in obese women with PCOS as compared with obese women without PCOS and in non-obese women with PCOS as compared with non-obese women without PCOS. Adiponectin concentrations correlated inversely with BMI, waist circumference (WC), total fat mass, serum insulin, and HOMA-IR in PCOS group. However, multiple regression analysis showed that BMI was the only independent determinant of adiponectin concentration. Conclusion: Our results suggest that insulin sensitivity per se probably does not play any role in the control of adipokines levels such as adiponectin, TNF-α and IL-6 in PCOS women (J Kor Diabetes Assoc 30:104~111, 2006). 연구배경: 다낭성 난소증후군 (PCOS)은 특징적으로 인슐린저항성이 잘 동반되는 것으로 알려져 있으나 그 기전은 정확히 밝혀져 있지 않으며, 아디포카인이 PCOS에서 비만과 무관하게 인슐린저항성과 관련이 있는지에 대해서는 논란이 있다. 따라서 저자들은 한국인 PCOS 환자에서 혈중 아디포카인 농도가 인슐린저항성과 연관이 있는지를 알아보고자 하였다. 방법: 13명의 비만한 PCOS환자, 15명의 비만하지 않은 PCOS환자, 8명의 비만한 대조군, 8명의 비만하지 않은 대조군에서 혈청 아디포넥틴, TNF-α, IL-6와 인슐린 감수성 지표를 측정하여 이들의 상호관계를 관찰하였다. 결과: HOMA-IR은 비만한 PCOS군과 비만한 대조군 사이에서는 차이가 없었으나 비만하지 않은 PCOS군에서는 비만하지 않은 대조군에 비하여 높았다. 아디포넥틴 농도는 PCOS군과 대조군 모두 비만한 경우 낮게 나타났으나 아디포넥틴, TNF-α 및 IL-6 농도는 비만한 PCOS군과 비만한 대조군 사이에 차이가 없었으며, 비만하지 않은 PCOS군과 비만하지 않은 대조군 사이에서도 차이가 없었다. PCOS군에서 아디포넥틴 농도는 BMI, 허리둘레, 지방량, 공복 인슐린 농도 및 HOMA-IR과 음의 상관관계가 있었다. 그러나 대조군에서는 아디포넥틴 농도가 다른 변수와 상관관계를 보이지 않았다. 아디포넥틴을 종속변수로 한 다중회귀분석에서는 이변량 상관관찰에서 상관관계를 보이던 공복 인슐린 농도와 HOMA-IR은 의미가 없었다. TNF-α와 IL-6 농도는 PCOS군과 대조군에서 모두 다른 변수들과 상관관계를 보이지 않았다. 비만하지 않은 PCOS군에서 이변량 상관관찰에서 HOMA-IR과 상관관계가 있는 변수는 허리둘레, 지방량 등이었으며, QUICKI는 BMI, 허리둘레, SHBG 등과 의미 있는 상관관계를 보였다.

Efficacy of gastro-retentive forms of ecabet sodium in the treatment of gastric ulcer in rats

김주영,배현주,최정섭,임종래,김상욱,이성훈,박은석 대한약학회 2014 Archives of Pharmacal Research Vol.37 No.8

The purpose of the present study is to investigatethe influence of gastric retention of ecabet sodium(ECS) on its mucoprotective effect in rat ulcer models. Mini-tablets containing 9 mg ECS were prepared using thedirect compression method. The release rates of ECS minitabletswere controlled by the amount and viscosity gradeof hydroxypropylmethyl cellulose incorporated. Gastricretention of ECS mini-tablets after oral administration torats was visually confirmed using a fluorescence imagingsystem. Because ECS mini-tablets exhibited size-dependentgastric retention, their gastric retention time wasprolonged as the release rate decreased. In the in vivoefficacy study, gastro-retentive dosage forms of ECS didnot influence the mucoprotective effect in the immediateirritation model but enhanced the effect in the delayedirritation model compared with ECS suspension. Thisfinding indicates that the duration of the mucoprotectiveeffect of ECS can be extended by the employment ofgastro-retentive dosage formulations and provides a rationalefor development of ECS gastro-retentive dosageforms.

급전점에 따른 유전체 기판의 비유전율 오차측정

이자열(J. Y. Lee),김종래(J. L. Kim),임인성(I. S. Yim),안동식(D. S. Ahn),오승엽(S. H. Oh) 한국통신학회 1999 한국통신학회 학술대회논문집 Vol.1999 No.7

DBS용 저 잡음 증폭기 설계 및 제작

이자열(J.Y.Lee),김종래(J.L.Kim),임인성(I.S.Yim),한상철(S.C.Han),오승엽(S.H.Oh) 한국통신학회 2000 한국통신학회 학술대회논문집 Vol.2000 No.7

회원 학술보고 : 구두발표 / 2. [3H] - Methotrexate - Lactosaminate Bovine Serume Albumin 공유결합체의 생쥐에서의 간표적성 및 체내동태에 대한 연구

김종국(Chong Kook Kim),임종래(Jong Lea Lim) 한국약제학회 1992 한국약제학회 총회 및 학술대회 요지집 Vol.- No.22

말레인산 암로디핀 정 5 mg과 베실산 암로디핀 정 5 mg의약동학 특성 및 안전성 비교

최희연,김재우,임형석,조상헌,김종률,최상민,정진아,임종래,배균섭 대한임상약리학회 2012 Translational and Clinical Pharmacology Vol.20 No.1

Background: Amlodipine is a third-generation dihydropyridine calcium channel blocker for treating hypertension. Though marketed primarily as a besylate salt, there have been some efforts to find other comparable salts. Among them, maleate is the salt that has been considered favorable for many drugs. The aim of this study was to compare the pharmacokinetics, as well as safety and tolerability of amlodipine maleate with amlodipine besylate. Methods: This study was open, randomized, two-period crossover design investigated in twelve healthy male volunteers over a 144 h period after administrating two forms of amlodipine 5 mg, respectively. Each period was separated with 2 weeks. Plasma concentrations of amlodipine were determined by liquid chromatography-tandem mass spectrometry. Safety profiles were assessed by vital signs, physical examinations, electrocardiograms, laboratory testing and adverse events monitoring. Results: All subjects were completed this study. Geometric mean ratios (GMRs) of amlodipine maleate/amlodipine besylate of Cmax and AUClast for amlodipine were 0.92 (90 % confidence interval, 0.81 ∼ 1.05) and 1.05 (0.96 ∼ 1.16), respectively. No serious adverse events were reported, and no clinically relevant changes were observed in safety profiles during this trial. Conclusion: Pharmacokinetics, tolerability and the safety were comparable between amlodipine maleate and amlodipine besylate in healthy individuals.

말레인산 암로디핀 정 5 mg과 베실산 암로디핀 정 5 mg의 약동학 특성 및 안전성 비교

최희연,김재우,임형석,조상헌,김종률,최상민,정진아,임종래,배균섭,Choi, Hee-Youn,Kim, Jae-Woo,Lim, Hyeong-Seok,Cho, Sang-Heon,Ghim, Jong-Lyul,Choe, Sang-Min,Jung, Jin-Ah,Lim, Jong-Lae,Bae, Kyun-Seop 대한임상약리학회 2012 臨床藥理學會誌 Vol.20 No.1

Background: Amlodipine is a third-generation dihydropyridine calcium channel blocker for treating hypertension. Though marketed primarily as a besylate salt, there have been some efforts to find other comparable salts. Among them, maleate is the salt that has been considered favorable for many drugs. The aim of this study was to compare the pharmacokinetics, as well as safety and tolerability of amlodipine maleate with amlodipine besylate. Methods: This study was open, randomized, two-period crossover design investigated in twelve healthy male volunteers over a 144 h period after administrating two forms of amlodipine 5 mg, respectively. Each period was separated with 2 weeks. Plasma concentrations of amlodipine were determined by liquid chromatography-tandem mass spectrometry. Safety profiles were assessed by vital signs, physical examinations, electrocardiograms, laboratory testing and adverse events monitoring. Results: All subjects were completed this study. Geometric mean ratios (GMRs) of amlodipine maleate/amlodipine besylate of $C_{max}$ and $AUC_{last}$ for amlodipine were 0.92 (90% confidence interval, 0.81 ~ 1.05) and 1.05 (0.96 ~ 1.16), respectively. No serious adverse events were reported, and no clinically relevant changes were observed in safety profiles during this trial. Conclusion: Pharmacokinetics, tolerability and the safety were comparable between amlodipine maleate and amlodipine besylate in healthy individuals.

메바코 정 ( 로바스타틴 20mg ) 에 대한 로바로드 정의 생물학적 동등성

송우헌(Woo Heon Seng),김정민(Jung Min Kim),조성완(Seong Wan Cho),김재현(Jae Hyun Kim),임종래(Jong Lae Lim),신희종(Hee Jong Shin),최영욱(Young Wook Choi) 한국약제학회 1998 Journal of Pharmaceutical Investigation Vol.28 No.4

Lovastatin, one of the potent cholesterol-lowering agents, is an inactive lactone prodrug which is metabolized to its active open acid, lovastatin acid (LVA). Bioequivalence study of two lovastatin preparations, the test drug (Mevacor^ⓡ: Chungwae Pharmaceutical Co., Ltd.) and the reference drug (Lovaload^ⓡ: Chong Kun Dang Pharmaceutical Co., Ltd.), was conducted according to the guidelines of Korea Food and Drug Administration (KFDA). Fourteen healthy male volunteers, 23.9±3.9 years old and 67.6±8.0 ㎏ of body weight in average, were divided randomly into two groups and administered the drug orally at the dose of 160 ㎎ as lovastatin in a 2×2 crossover study. Plasma concentrations of lovastatin acid were analysed by HPLC method for 12 hr after administration. The extent of bioavailability was obtained from the plasma concentration-time profiles of total lovastatin acid after alkaline hydrolysis of the plasma samples. By alkaline hydrolysis, trace amounts of unmetabolized lovastatin were converted to lovastatin acid. The AUC_(0-12hr) was calculated by the linear trapezoidal rule method. The C_(max) and T_(max) were compiled directly from the plasma drug concentration-time data. Student`s t-test indicated no significant differences between the formulations in these parameters. Analysis of variance (ANOVA) revealed that there were no differences in AUC, C_(max), and T_(max) between the formulations. The apparent differences between the formulations were far less than 20% (e.g., 7.07, 5.77 and 1.18% for AUC, C_(max), and T_(max), respectively). Minimum detectable differences(%) between the formulations at α=0.05 and 1-β=0.8 were less than 20% (e.g., 17.2, 15.1, and 15.9% for AUC, Cmax, and Tmax, respectively). The 90% confidence intervals for these parameters were also within ±20% (e.g., -5.20∼19.3, -5.00∼16.5, and -10.2∼12.5% for AUC, C_(max), and T_(max), respectively). These results satisfied the bioequivalence criteria of KFDA guidelines, indicating that the two formulations of lovastatin were bioequivalent.